74885-67-9

Basic information

• Product Name: 4-hydrazinylbenzamide
• Synonyms: 4-hydrazinylbenzamide;Benzamide, 4-hydrazino- (9CI);BenzaMide, 4-hydrazino-;4-hydrazinylbenzamide HCl
• CAS NO: 74885-67-9
• Molecular Formula: C7H9N3O
• Molecular Weight: 151.16586
• Product Categories: AMIDE
• Mol File: 74885-67-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 389.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.317±0.06 g/cm3(Predicted)
• PKA: 16.69±0.50(Predicted)
• CAS DataBase Reference: 4-hydrazinylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-hydrazinylbenzamide(74885-67-9)
• EPA Substance Registry System: 4-hydrazinylbenzamide(74885-67-9)

Safety Data

• Hazardous Substances Data: 74885-67-9(Hazardous Substances Data)

Usage

General Description

4-hydrazinylbenzamide is a chemical compound with the molecular formula C7H8N4O. It is a derivative of benzamide, containing a hydrazine functional group that makes it potentially useful for various applications in chemical and pharmaceutical research. 4-hydrazinylbenzamide has been studied for its ability to act as an inhibitor of enzymes involved in the growth and proliferation of cancer cells, making it a potential candidate for anti-cancer drug development. Its hydrazine moiety also has the potential to be used in the synthesis of other organic compounds and in various chemical reactions. The compound has potential applications in the fields of medicinal chemistry, biochemistry, and organic synthesis.

Upstream product

• 2835-68-9 4-aminobenzamide 

Downstream Products

• 40948-51-4 C₁₁H₁₁N₃O₂ 

Relevant articles and documents

Virtual ligand screening of the p300/CBP histone acetyltransferase: Identification of a selective small molecule inhibitor

The histone acetyltransferase (HAT) p300/CBP is a transcriptional coactivator implicated in many gene regulatory pathways and protein acetylation events. Although p300 inhibitors have been reported, a potent, selective, and readily available active-sitedirected small molecule inhibitor is not yet known. Here we use a structure-based, in silico screening approach to identify a commercially available pyrazolone- containing small molecule p300 HAT inhibitor, C646. C646 is a competitive p300 inhibitor with a Ki of 400 nM and is selective versus other acetyltransferases. Studies on site-directed p300 HAT mutants and synthetic modifications of C646 confirm the importance of predicted interactions in conferring potency. Inhibition of histone acetylation and cell growth by C646 in cells validate its utility as a pharmacologic probe and suggest that p300/CBP HAT is a worthy anticancer target.